Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Mitotic count reflects prognosis of gallbladder cancer particularly among patients with T3 tumor.

Kai K, Masuda M, Ide T, Takase Y, Miyoshi A, Kitahara K, Miyazaki K, Noshiro H, Tokunaga O.

Mol Clin Oncol. 2013 Jul;1(4):633-638. Epub 2013 May 16.

2.

Gallbladder cancer: Clinical and pathological approach.

Kai K, Aishima S, Miyazaki K.

World J Clin Cases. 2014 Oct 16;2(10):515-21. doi: 10.12998/wjcc.v2.i10.515. Review.

3.

Tumor budding and dedifferentiation in gallbladder carcinoma: potential for the prognostic factors in T2 lesions.

Kai K, Kohya N, Kitahara K, Masuda M, Miyoshi A, Ide T, Tokunaga O, Miyazaki K, Noshiro H.

Virchows Arch. 2011 Oct;459(4):449-56. doi: 10.1007/s00428-011-1131-9. Epub 2011 Jul 22.

PMID:
21785869
4.

Squamous cell carcinoma of the oropharynx: Ki-67 and p53 can identify patients at high risk for local recurrence after surgery and postoperative radiotherapy.

Grabenbauer GG, Mühlfriedel C, Rödel F, Niedobitek G, Hornung J, Rödel C, Martus P, Iro H, Kirchner T, Steininger H, Sauer R, Weidenbecher M, Distel L.

Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):1041-50.

PMID:
11072161
5.

Tumour infiltrating lymphocytes as an independent prognostic factor in transitional cell bladder cancer.

Lipponen PK, Eskelinen MJ, Jauhiainen K, Harju E, Terho R.

Eur J Cancer. 1992;29A(1):69-75.

PMID:
1445749
6.

Post-operative lymphocyte count may predict the outcome of radical resection for gallbladder carcinoma.

Iwase R, Shiba H, Haruki K, Fujiwara Y, Furukawa K, Futagawa Y, Wakiyama S, Misawa T, Yanaga K.

Anticancer Res. 2013 Aug;33(8):3439-44.

PMID:
23898116
7.

Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.

Stavropoulos NE, Filiadis I, Ioachim E, Hastazeris K, Tsimaris I, Kalogeras D, Stefanaki S, Agnantis NJ.

Anticancer Res. 2002 Nov-Dec;22(6B):3759-64.

PMID:
12552989
8.

Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.

Kim ST, Jeong H, Woo OH, Seo JH, Kim A, Lee ES, Shin SW, Kim YH, Kim JS, Park KH.

Am J Clin Oncol. 2013 Jun;36(3):224-31. doi: 10.1097/COC.0b013e3182467d90.

PMID:
22495453
9.

The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.

Korkolopoulou P, Christodoulou P, Kapralos P, Exarchakos M, Bisbiroula A, Hadjiyannakis M, Georgountzos C, Thomas-Tsagli E.

Pathol Res Pract. 1997;193(11-12):767-75.

PMID:
9521509
10.

Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma.

Tomsová M, Melichar B, Sedláková I, Steiner I.

Gynecol Oncol. 2008 Feb;108(2):415-20. Epub 2007 Nov 26.

PMID:
18037158
12.

Immunophenotypic features of tumor infiltrating lymphocytes from mammary carcinomas in female dogs associated with prognostic factors and survival rates.

Estrela-Lima A, Araújo MS, Costa-Neto JM, Teixeira-Carvalho A, Barrouin-Melo SM, Cardoso SV, Martins-Filho OA, Serakides R, Cassali GD.

BMC Cancer. 2010 Jun 4;10:256. doi: 10.1186/1471-2407-10-256.

13.

Clinicopathological significance of HuR expression in gallbladder carcinoma: with special emphasis on the implications of its nuclear and cytoplasmic expression.

Sun DP, Lin CY, Tian YF, Chen LT, Lin LC, Lee SW, Hsing CH, Lee HH, Shiue YL, Huang HY, Li CF, Liang PI.

Tumour Biol. 2013 Oct;34(5):3059-69. doi: 10.1007/s13277-013-0872-2. Epub 2013 May 31.

PMID:
23722602
14.

Serial analysis of gene expression identifies connective tissue growth factor expression as a prognostic biomarker in gallbladder cancer.

Alvarez H, Corvalan A, Roa JC, Argani P, Murillo F, Edwards J, Beaty R, Feldmann G, Hong SM, Mullendore M, Roa I, Ibañez L, Pimentel F, Diaz A, Riggins GJ, Maitra A.

Clin Cancer Res. 2008 May 1;14(9):2631-8. doi: 10.1158/1078-0432.CCR-07-1991.

15.

Lymphatic invasion: an important prognostic factor for stages T1b-T3 gallbladder cancer and an indication for additional radical resection of incidental gallbladder cancer.

Shibata K, Uchida H, Iwaki K, Kai S, Ohta M, Kitano S.

World J Surg. 2009 May;33(5):1035-41. doi: 10.1007/s00268-009-9950-4.

PMID:
19225832
16.

The prognostic significance of p53, p27 kip1, p21 waf1, HER-2/neu, and Ki67 proteins expression in gastric cancer: a clinicopathological and immunohistochemical study of 121 Arab patients.

Al-Moundhri MS, Nirmala V, Al-Hadabi I, Al-Mawaly K, Burney I, Al-Nabhani M, Thomas V, Ganguly SS, Grant C.

J Surg Oncol. 2005 Sep 15;91(4):243-52.

PMID:
16121348
17.

Mutated p53 protein expression and proliferative activity in advanced gastric cancer.

Ikeguchi M, Saito H, Kondo A, Tsujitani S, Maeta M, Kaibara N.

Hepatogastroenterology. 1999 Jul-Aug;46(28):2648-53.

PMID:
10522058
18.

Early results of the value of p53 in predicting survival in a homogeneous cohort of patients with invasive bladder cancer treated with a neoadjuvant carboplatin-based regimen (M-CAVI).

Ribas A, Bellmunt J, Albanell J, De Torres I, Bermejo B, De Torres JA, Morote J, Gallardo E, Vera R, Carulla J, Sole-Calvo LA.

Tumori. 1996 Nov-Dec;82(6):554-9.

PMID:
9061063
19.
20.

Prognostic significance of immunohistochemically localized biomarkers in stage II and stage III breast cancer: a multivariate analysis.

Bhatavdekar JM, Patel DD, Shah NG, Vora HH, Suthar TP, Chikhlikar PR, Ghosh N, Trivedi TI.

Ann Surg Oncol. 2000 May;7(4):305-11.

PMID:
10819372
Items per page

Supplemental Content

Write to the Help Desk